Display options
Cite
Mori K, Suzuki T, Igarashi T, et al. Persistent hyperglycemia modulates gut immune function and microbiota in rats. J Intensive Care. 2015;3(1):34doi: 10.1186/s40560-015-0101-8.
Mori, K., Suzuki, T., Igarashi, T., Inoue, K., Asahara, T., Nomoto, K., Seki, H., Yamada, T., Minamishima, S., Kosugi, S., Katori, N., & Morisaki, H. (2015). Persistent hyperglycemia modulates gut immune function and microbiota in rats. Journal of intensive care, 3(1), 34. https://doi.org/10.1186/s40560-015-0101-8
Mori, Katsuya, et al. "Persistent hyperglycemia modulates gut immune function and microbiota in rats." Journal of intensive care vol. 3,1 (2015): 34. doi: https://doi.org/10.1186/s40560-015-0101-8
Mori K, Suzuki T, Igarashi T, Inoue K, Asahara T, Nomoto K, Seki H, Yamada T, Minamishima S, Kosugi S, Katori N, Morisaki H. Persistent hyperglycemia modulates gut immune function and microbiota in rats. J Intensive Care. 2015 Jul 23;3(1):34. doi: 10.1186/s40560-015-0101-8. eCollection 2015. PMID: 26207186; PMCID: PMC4511975.
Copy Download .nbib Format: NLM
Share it on

J Intensive Care. 2015 Jul 23;3(1):34. doi: 10.1186/s40560-015-0101-8. eCollection 2015.

Persistent hyperglycemia modulates gut immune function and microbiota in rats.

Journal of intensive care

Katsuya Mori, Takeshi Suzuki, Toru Igarashi, Kei Inoue, Takashi Asahara, Koji Nomoto, Hiroyuki Seki, Takashige Yamada, Shizuka Minamishima, Shizuko Kosugi, Nobuyuki Katori, Hiroshi Morisaki

Affiliations

  1. Department of Anesthesiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582 Japan.
  2. Yakult Central Institute for Microbiological Research, 5-11 Izumi, Kunitachi-shi, Tokyo 186-0012 Japan.

PMID: 26207186 PMCID: PMC4511975 DOI: 10.1186/s40560-015-0101-8

Abstract

BACKGROUND: Since hyperglycemia-induced cellular dysfunction could be associated with alterations of the immune system, we tested the hypothesis that hyperglycemia augments the aberrant immune responses such as inflammation and differentiation of CD4(+) T lymphocytes in the mesenteric lymph nodes (MLNs), and induces alterations of microbiota both under physiological and pathological conditions.

METHODS: Male Wistar rats were randomly allocated into 4 groups: Control and Endotoxemia (lipopolysaccharide, LPS 1 mg/kg) with or without hyperglycemia. The hyperglycemia groups were administered glucose solution (10-40 %), while the normoglycemia groups were administered saline. Alterations of the mRNA expressions of inflammatory cytokines and CD4(+) T lymphocyte transcriptional factor expressions in the MLNs, and those of the intestinal microbiota were analyzed at 24 hr.

RESULTS: Hyperglycemia was kept approximately 250-350 mg/dL during the 24 hr study period. At the end of 24 hr, hyperglycemia augmented the mRNA expressions of interleukin (IL)-1β and IL-6 in the MLNs, while both the helper T (Th) 2 and regulatory-T (Treg) transcriptional factors were simultaneously up-regulated under non-endotoxemic condition. LPS injection significantly modulated the obligate anaerobe bacterial populations of the Bacteroidetes class, and altered the population sizes of the Clostridium perfringens and the Bacteroides fragilis subgroup. Hyperglycemia did not enhance these alterations of the microbiota evoked by LPS, although it did modify the bacterial populations of the L. reuteri subgroup and staphylococci in healthy condition without endotoxemia.

CONCLUSIONS: The present study indicates that both gut immune function and microbiota are significantly modulated by persistent hyperglycemia.

Keywords: CD4+ T lymphocyte subsets; Gut barrier function; Mesenteric lymph nodes; Pro-inflammatory cytokine

References

  1. Biochem Biophys Res Commun. 1991 Jan 15;174(1):18-24 - PubMed
  2. Int J Mol Med. 2013 Oct;32(4):795-804 - PubMed
  3. Immunology. 2013 Jan;138(1):1-11 - PubMed
  4. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3360-5 - PubMed
  5. Nat Rev Immunol. 2004 Jun;4(6):478-85 - PubMed
  6. Appl Environ Microbiol. 2012 Aug;78(15):5119-26 - PubMed
  7. Nat Immunol. 2005 Nov;6(11):1069-70 - PubMed
  8. Crit Care Med. 2005 Jul;33(7):1624-33 - PubMed
  9. Dig Dis Sci. 2011 Apr;56(4):1171-7 - PubMed
  10. J Microbiol Methods. 1999 Sep;37(3):215-21 - PubMed
  11. Eur J Immunol. 2012 Dec;42(12):3150-66 - PubMed
  12. Endocrinology. 2007 Jan;148(1):346-53 - PubMed
  13. Crit Care Med. 2009 Dec;37(12):3001-9 - PubMed
  14. N Engl J Med. 2003 Jan 9;348(2):138-50 - PubMed
  15. Crit Care Med. 2005 Dec;33(12 Suppl):S506-9 - PubMed
  16. N Engl J Med. 2001 Nov 8;345(19):1359-67 - PubMed
  17. Crit Care Med. 2003 Jul;31(7):2068-71 - PubMed
  18. Endocrinology. 2006 May;147(5):2518-25 - PubMed
  19. Appl Environ Microbiol. 2009 Apr;75(7):1961-9 - PubMed
  20. EMBO Rep. 2013 Apr;14(4):319-27 - PubMed
  21. Circulation. 2002 Oct 15;106(16):2067-72 - PubMed
  22. BMC Immunol. 2012 Apr 14;13:19 - PubMed
  23. Diabetes. 2006 Dec;55(12):3446-54 - PubMed
  24. Am J Physiol. 1997 Aug;273(2 Pt 1):G314-21 - PubMed
  25. J Interferon Cytokine Res. 2012 Aug;32(8):341-9 - PubMed
  26. Crit Care Med. 2009 Mar;37(3):1024-30 - PubMed
  27. Annu Rev Med. 2009;60:97-110 - PubMed
  28. N Engl J Med. 2013 Aug 29;369(9):840-51 - PubMed
  29. Alcohol. 2004 Jul;33(3):199-208 - PubMed
  30. Int J Biochem Cell Biol. 2013 Jul;45(7):1246-54 - PubMed
  31. Ann N Y Acad Sci. 2010 Oct;1207 Suppl 1:E86-93 - PubMed

Publication Types